Fate Therapeutics FATE is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement.
Analysts estimate that Fate Therapeutics will report an earnings per share (EPS) of $-0.89.
Fate Therapeutics bulls will hope to hear the company to announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
Historical Earnings Performance
Last quarter the company beat EPS by $0.03, which was followed by a 0.79% drop in the share price the next day.
Here's a look at Fate Therapeutics's past performance and the resulting price change:
|Quarter||Q2 2022||Q1 2022||Q4 2021||Q3 2021|
|Price Change %||-0.79%||-11.4%||-0.38%||2.97%|
Shares of Fate Therapeutics were trading at $20.99 as of November 01. Over the last 52-week period, shares are down 65.36%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.